Management Forum Logo

Presented by
Management Forum

The Common Technical Document Training Course

A comprehensive review of the regulations and technical requirements for chemistry, manufacturing and control (CMC) management of your application.

★★★★★ "The speaker was excellent, with a lot of knowledge and experience. I really liked the examples on wh... more (35)"

8-9 July 2024
+ 25-26 November 2024 »

from £1099

Need help?  Enrol or reserve

Course Overview

This interactive two-day course will provide you with a clear and comprehensive understanding of the regulatory and technical requirements for CMC management of your full and generic application in major markets of the EU and USA. Furthermore, the course examines the requirements for global roll-out of the dossier to ROW regions including LATAM, ASEAN, MENA and CIS territories.

You will increase your ability to manage all aspects of development of the CMC applications after two days of intensive lectures, group work and discussion sessions, covering everything you need to know about compiling the chemistry and pharmacy section of your generic dossier.

Skills you will gain include:

  • Effective compilation of the Common Technical Document (CTD) and critical review of documentation
  • Quality by design (QbD), critical attributes and developing new product using the CQA pyramid model
  • Compiling and submitting Module 3 (CTD) of your registration dossier
  • Identifying the extent of content expected by EU and US regulators
  • Achieving the quickest turnaround of your submission
  • Managing the pharmaceutical and quality aspects of your developments and registration dossier in Europe and the US
  • Ensuring right-first-time development
  • Meeting the legal framework and guidelines for the CMC/quality part of the dossier and links to GMP

This course is part of our GxP training (Good x Practice) course collection, which features a variety of topic areas to ensure you comply with the most recent quality guidelines. For more information on the latest EU GMP regulations, see our GMP training course covering the Annex 1.

Who should attend

  • Senior analytical chemists
  • Formulation chemists
  • Technical services chemists
  • Registration staff (all levels)
  • Quality managers
  • Quality control directors
  • R&D project managers

Enrol or reserve

This course will cover:

What is the CTD?

  • Pharmaceutical medicine and documents
  • Introduction to CTD, ICH and eCTD
  • Introduction to data standards relevant to module 3 (incl. EMA SPOR, ISO-IDMP)

The importance of chemistry/manufacturing and controls (CMC)

  • Setting the scene for the module 3 deep-dive

Assessment of biologics and why the CMC section for these products is more extensive

A deep-dive in Module 3 – examining the content of all sections

  • Module 3.2 for the substances (32S)
  • Module 3.2 for the final products (32P)
  • Appendices and regional information in Module 3 (32A and 32R)
  • Additional data for generics in the US (ANDA tables)
  • Process validation deep-dive (S25 + P35)
  • Comparability across batches (ICH Q5E)
  • Quality-by-Design and Quality Target Product Profile (ICH Q8, Q9 and Q10)
  • Analytical method deep-dive (ICH Q2 and beyond)
  • Process analytical technology
  • Pharmaceutical quality system (ICH Q10)

Post-approval maintenance

  • What and why?
  • EU eCTD lifecycle management
  • US eCTD lifecycle management
  • Product lifecycle management (ICH Q12) and established conditions

Potential scenario’s for Module 3

  • EDQM certificate of suitability of monographs of European pharmacopeia (CoS/CEP)
  • Active substance master file (ASMP)
  • US drug master files (DMFs)

Basic principles for eCTD authors (incl. focus on global dossier roll-out)

  • Separating content from contexts
  • Applying the right document granularity
  • Lean and structured authoring

Trends, developments and future outlook

  • Identification of medicinal products (IDMP)
  • FDA Knowledge-Aided-Structured-Assessment and Structured-Application (FDA-KASA)
  • FDA Pharmaceutical quality/Chemistry manufacturing and control (PQ/CMC) data elements
  • EMA Digital Application Dataset Integration (DADI) project
  • Accumulus synergy – global information exchange platform

Summary of Module 3 and what should stand out from the Quality Overall Summary (module 2)

Enrol or reserve

Andrew Willis
San Salvatore Training Ltd

Andrew Willis is an independent consultant providing expert advice and training on global regulatory solutions and pharmaceutical development. Previously, he worked for Catalent Pharma Solutions as VP Regulatory Affairs & Consulting Services, where he was head of a team of internal and external regulatory affairs consultants.

He qualified as a Chemist from the University of Glamorgan, after which he furthered his understanding of pharmaceutical development, working as a research chemist with Parke Davis. He had 10 years manufacturing and analytical experience prior to entering regulatory affairs as a Senior Executive Officer with responsibility for submission of European MAAs and project management of development programs. He has over 30 years’ pharmaceutical experience with extensive knowledge in the development and manufacture of sterile, solid oral, inhalation, topical and biotech pharmaceutical products. These experiences have allowed knowledge of many biotech products requirements with experiences of growth hormones and multiple cancer treatments, including development and clinical registration of the first genetically modified live bacterium for such treatment.
He has extensive experience of major European and US regulatory projects, in the clinical and marketing authorisation stages, and has significant experience in coordinating and managing meetings with European and US Health Authorities.

More details

NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:

  • 30% off the 2nd delegate*
  • 40% off the 3rd delegate*
  • 50% off the 4th delegate*

Please contact us for pricing if you are interested in booking 5 or more delegates

8-9 July 2024

Live online

09:00-17:00 UK (London) (UTC+01)
10:00-18:00 Paris (UTC+02)
04:00-12:00 New York (UTC-04)
Course code 13763

  • GBP 1,299
  • EUR 1,869
  • USD 2,129

View basket 

Not ready to book yet?

for 7 days, no obligation

25-26 November 2024

Live online

09:00-17:00 UK (London) (UTC+00)
10:00-18:00 Paris (UTC+01)
04:00-12:00 New York (UTC-05)
Course code 14045

  • GBP 1,099 1,299
  • EUR 1,589 1,869
  • USD 1,817 2,129

Until 21 Oct

View basket 

Not ready to book yet?

for 7 days, no obligation

* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price; and apply only when booking multiple delegates on the same date.

Reviews of IPI's The Common Technical Document training course

The speaker was excellent, with a lot of knowledge and experience. I really liked the examples on which we practised what needs to be included in some CTD dossier.

Mar 12 2024

Martina Kunštić
RA Specialist , Genera Inc./Dechra Pharmaceuticals

Mar 12 2024

The webinar has great content for us who work with CTD's in the pharma industry, I think there was so much helpful information on this for beginners and medium level on CTD. I think Andrew is great and gives a truly expert opinion, he demonstrated his expertise and really had you thinking.

Gabriela Gutierrez
International Regulatory Affairs Specialist, Zeyco

Nov 28 2022

very good, well organized

Evdoky Harran
Regulatory Affairs Associate, Pierre Fabre

Nov 28 2022

Very good

Richa Dcruz
officer, Shorla Oncology

Jul 18 2022

Content is well designed and flowing the step by step informative topics. Presentation - well presented and weighed on important sections. Speaker - very interactive and made easy to understand. He is taking interest to answer the questions until I was clear about topics. He has focused on the key sections and explained in details about it. Interactive sessions are really good and keep my self engaged throughout the training.

Nikhil Soni
Regulatory Affairs Specialist, Thermofisher Scientific Limited

Jul 18 2022

The speaker has the required knowledge for the course as well as a wide experience. In general all the webinar was interesting.

Isabel Villanueva Gonzalez
regulatory affairs technician, Zendal

Jul 6 2021

An excellent 2 days - required lots of concentration but worth it. It was very engaging and encouraged me to continue learning and improving.

Jane Kean
Regulatory Associate, Elanco UK AH Limited

Dec 4 2019

The speaker is really an expert on the CTD requirements and teaches the mindset required to make up a good dossier. I learned a lot from this course.

Wendy Masman
Regulatory Affairs Officer, Beaphar B.V.

Dec 4 2019

It was one of the best workshops I have attended: content was according to expectations, all questions were answered, presenter was passionate and kept the energy high during the presentations.

Iris Vanwelkenhuysen
CMC Dossier Leader, Galapagos

Dec 4 2019

Great speaker, capable of transmitting his knowledge in an enjoyable and interactive way.

Rocio Arias
Regulatory Affairs Technician , Pharmex Advanced Laboratories, S.L.

Dec 4 2019

Excellent presentation by a first-class speaker who has a wealth of knowledge. I particularly liked the interactive exercises.

Wil Pantin
New Product Introduction Manager, M & A Pharmachem Ltd

Jul 3 2019

Good speaker, updated information and good discussions. The group assignments were terrific for learning and understanding.

Hilde Reiersen
Research Scientist, GE Healthcare AS

Jul 3 2019


Vilma Smith
Senior Manager, Global Regulatory CMC, Bristol Myers Squibb

Jul 3 2019

The speaker was not only very professional, but also kept the mood light and fun. I enjoyed his way of putting things into perspective and making me think in a whole other way from what I am used to. The exercises ... helped with better understanding the material. Overall, a really good course and a great speaker giving both theoretical and practical tools to understand the CTD and importance of the Module 3.

Joanna Sadiq
Regulatory Manager, LINK Medical ApS

Dec 4 2018

Superbly knowledgable speaker and great training style - content was very helpful

Andrew Germain
Associate Director, CMC Regulatory Affairs, GW Pharmaceuticals

Dec 4 2018

Excellent speaker! Good interaction! Wonderful course.

Marjana Grønvall
Regulatory affairs professional, ALK-Abelló A/S

Jul 4 2018

Very lively presentation, interactivity, exercises to keep the interest.

Natacha Gonzalez
CMC Dossier & Compliance Specialist, Ares Trading S.A.

Jul 4 2018

Very clean. Very clear speaker. Presentation and content are well adapted.

Sonia Bchir Kassassi
Regulatory Affairs CMC Expert, GUERBET

Dec 5 2017

The content of presentation was very good and covered the major sections of CTD. The speaker was very keen to answer all questions.

Ewelina Dulko
Senior Formulation Scientist, Wockhardt

Dec 5 2017

Very interactive course. Very interesting.

Fanny Valleix
Head Clinical Research, ImmuPharma

Jul 5 2017

High quality training, speaker is really good with a lot of experience. Very useful information and advice shared with the group.

Slobodanka Cirin-Varadjan
Regulatory Affairs, Hemofarm A.D.

Jul 5 2017

Very detailed and informative. Speaker clearly very knowledgable on experiences and delivered the content in a clear and concise manner. Excellent transfer of information.

Ini Okereke
Regulatory Affairs Manager, GW Pharmaceuticals

Jul 5 2017


Camilla Costa
Regulatory Affairs Manager, Masters Speciality Pharma

Dec 5 2017

I really enjoyed the presentation, which I found really interesting.

Maria Biri
CMC Dossier Development & Coordination Supervisor, ELPEN Pharmaceutical Co. Inc.

Jul 5 2017

It is very good. I'm very glad that my company sent me on this course.

Nette Boylan
Regulatory Officer, CMC, Actavis UK Ltd, a subsidiary of Accord Healthcare Ltd

Jul 5 2017

Very professional

Evdoky Harran
Regulatory Affairs Associate, Pierre Fabre

Dec 5 2017

Experienced speaker

Julie de Smet
Regulatory Affairs Consultant, PharmaVize NV

Dec 14 2016

Overall information and guidance provided have been very useful and have been applied in my day to day work experience

Venita Furtado
Regulatory Consultant, Furtado Consultancy Limited

Dec 14 2016

The course content was extended so that not all the issues were discussed in-depth because there was not time, but the discussed parts and the approach used were excellent.

Laura Zecca
Scientific Coordination Officer, Ginsana

Dec 14 2016

Overall, the course is great and even better than I expected. I will definitely apply what I learned to my daily work.

Ying Zhao
Quality Assurance Manager, Genethics Regulatory Services

Jun 14 2016

Content of the course was as expected but a little too extensive for just 2 days, presentation was interesting and speaker professional and motivating

Gordana Sijan Zidaric
Regulatory Affairs Officer, Xellia Ltd

Jun 14 2016

On overall, the presentation was given in a proper organised way with more practical approach. I admire the speaker and his knowledge about the subject

Archana Sekharan
Regulatory Affairs Executive, Genethics Regulatory Services

Dec 14 2016

As stated above, I was very satisfied about the quality of the speaker, content of the course, structure, fact that there were some practical exercises, interactivity of the course.

Jan Luypaert
Regulatory Affairs Manager, PhaRA

Jun 14 2016

I have never attended a course with so few participants, but I actually liked and it made it easier to communicate, and also it forced us to be more proactive. Andrew Willis was very clearr in his presentations, but again many of these went very fast.

Nermin Ipek
Global Regulatory Affairs Manager, Ferring Pharmaceuticals Inc

Jun 14 2016

A course that is of value for a range of experiences, thank you

Robert Ellis
Principal Consultant CM&C, Elanco Animal Health

United Kingdom

  • Actavis UK Ltd, a subsidiary of Accord Healthcare Ltd
  • Bespak
  • Bespak Europe Ltd
  • Bristol Myers Squibb
  • CP Pharmaceuticals Limited
  • Elanco Animal Health
  • Elanco UK AH Limited
  • Ethypharm
  • Furtado Consultancy Limited
  • GE Healthcare Ltd.
  • Genethics Regulatory Services
  • GSK Consumer Health Care
  • GW Pharmaceuticals
  • GW Pharmaceuticals PLC
  • Ipsen Ltd
  • Lonza
  • M & A Pharmachem Ltd
  • Masters Speciality Pharma
  • Medreich Plc
  • Medreich Plc
  • Morningside Healthcare Limited
  • MSD
  • Niacet b.v.
  • Seqirus UK Ltd
  • Teva UK Ltd
  • Thermofisher Scientific Limited
  • Torbay Pharmaceuticals
  • Wockhardt
  • Wockhardt UK Ltd
  • Zentiva Group a.s.


  • ALK-Abelló A/S
  • Aurora Nordic Cannabis A/S
  • Ferring Pharmaceuticals A/S
  • Ferring Pharmaceuticals Inc
  • Ferrosan Medical Devices A/S
  • LEO Pharma A/S
  • LINK Medical ApS
  • Novo Nordisk A/S
  • UNION therapeutics


  • Actelion Pharmaceutical Ltd
  • Advanced Accelerator Applications
  • Ares Trading S.A.
  • Bracco Suisse SA
  • DNDi
  • Emergent BioSolutions Berna GmbH
  • Ginsana
  • Nestec SA
  • ObsEva SA


  • Camurus AB
  • Fresenius Kabi
  • Fresenius Kabi AB
  • Liansa Pharma Consulting AB
  • Recipharm
  • Recipharm AB
  • Recipharm Pharmaceutical Development AB


  • Groupe Guerbet
  • ImmuPharma
  • Maco Productions
  • Orphan Europe
  • Patheon France


  • EirGen Pharma Limited
  • Genzyme Ireland Limited
  • Genzyme Ireland Ltd
  • Rottapharm Ltd
  • Sanofi
  • Shorla Oncology


  • argenx
  • Galapagos
  • PhaRA
  • PHARA+
  • PharmaVize NV


  • Genera Inc
  • Genera inc./Dechra Pharmaceuticals
  • Xellia
  • Xellia Ltd


  • Beaphar B.V.
  • Bilthoven Biologicals
  • HHV Biotech
  • Johnson & Johnson
  • Sever Pharma Solutions


  • Faes Farma S.A.
  • Grifols S.A.
  • Instituto Grifols S.A
  • Pharmex Advanced Laboratories, S.L.
  • Zendal


  • Aurora Europe GmbH
  • Bayer AG
  • Sanofi-Aventis Deutschland GmbH


  • Chiesi farmaceutici
  • GlaxoSmithKline Vaccines & Diagnostics s.r.l.
  • Menarini Ricerche spa


  • dne pharma AS
  • GE Healthcare AS
  • Weifa AS

Slovak Republic

  • Ewopharma International s.r.o
  • Ewopharma International sro
  • Ewopharma International, s.r.o.


  • Liqvor


  • Ebewe Pharma


  • Biovet JSC


  • ELPEN Pharmaceutical Co. Inc.

Hong Kong

  • Fortune Pharmacal Company Limited


  • Gedeon Richter Ltd


  • NeuroDerm


  • Pierre Fabre


  • Zeyco


  • Valeant Pharma Poland sp.z o.o


  • Hemofarm A.D.

Enrol or reserve

Run The Common Technical Document Live online for your team

2 days

Typical duration

Pricing from:

  • GBP 800
  • Per attendee, based on 10 attendees
  • Course tailored to your requirements
  • At your choice of location, or online


We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.

Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:

Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra Beer

Aleksandra BEER
Training expert

Yesim Nurko

Training expert

+44 (0)20 7749 4749